Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Moleculin Biotech ( (MBRX) ) just unveiled an announcement.
On September 8, 2025, Moleculin Biotech announced the enrollment and treatment of the first subjects in the European Union for its pivotal Phase 2B/3 MIRACLE trial, which evaluates Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia. This trial, with active sites in the US, Spain, Ukraine, Georgia, and Romania, aims to recruit 45 subjects by the end of 2025 for initial data unblinding, marking a significant step in addressing the unmet need in treating second line R/R AML.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases, avoiding multidrug resistance mechanisms and lacking the cardiotoxicity common with other anthracyclines.
Average Trading Volume: 6,368,607
Technical Sentiment Signal: Sell
Current Market Cap: $11.36M
Learn more about MBRX stock on TipRanks’ Stock Analysis page.